GlassScriptPhysician profile
Tarak V Patel
NPI 1578751871
$3,475.94
in general payments reported to CMS, 2019-2025
20 companies · $58.82 in 2025
The $58.82 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $160 · 2021: $878 · 2022: $1,176 · 2023: $447 · 2024: $58.24 · 2025: $58.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.22 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $683.69 | 2019-2023 | Kimyrsa, Vabomere, Rezzayo |
| Cipla USA INC. | $439.89 | 2021-2022 | |
| Viiv Healthcare Company | $420.10 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $355.77 | 2019-2025 | Delstrigo, Dificid, Pifeltro |
| Insmed, INC. | $349.85 | 2019-2025 | Arikayce |
| La Jolla Pharmaceutical Company | $252.37 | 2021-2023 | Xerava |
| Abbvie INC. | $156.40 | 2021-2023 | |
| Cumberland Pharmaceuticals, INC. | $136.57 | 2022 | |
| Gilead Sciences, INC. | $108.22 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $105.90 | 2021-2023 | Nuzyra |
| Argon Medical Devices, INC. | $96.44 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $91.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $74.79 | 2019-2020 | |
| Trisalus Life Sciences, INC. | $58.24 | 2024 | Trinav Infusion System |
| Shionogi INC | $29.99 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.68 | 2019 | |
| Janssen Biotech, INC. | $23.99 | 2023 | Symtuza |
| Edwards Lifesciences Corporation | $23.17 | 2021 | |
| Ferring Pharmaceuticals INC. | $21.72 | 2023 | Rebyota |
| Angiodynamics, INC. | $21.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.